-
Product Insights
New![]()
Ewing Sarcoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Ewing Sarcoma Clinical Trials Overview The Ewing Sarcoma clinical trial report consists of 430 trials. The report provides an overview of the Ewing Sarcoma clinical trials scenario. The report provides top-line data relating to the clinical trials on Ewing Sarcoma. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RNAi Gene Therapy to Inhibit EWS-FLI1 for Ewing Sarcoma in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RNAi Gene Therapy to Inhibit EWS-FLI1 for Ewing Sarcoma in Ewing Sarcoma Drug Details: RNAi...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cyclosam in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Cyclosam in Ewing Sarcoma Drug Details: Cyclosam is under development for the treatment of osteosarcoma, Ewing...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Racemetyrosine in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Racemetyrosine in Ewing Sarcoma Drug Details: Racemetyrosine (SM-88) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Toripalimab in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Toripalimab in Ewing Sarcoma Drug Details: Toripalimab (Tuoyi) is a monoclonal antibody, acts as an...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lurbinectedin in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lurbinectedin in Ewing Sarcoma Drug Details: Lurbinectedin (Zepzelca) is a synthetic tetrahydropyrrolo [4, 3, 2-de]...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lenvatinib Mesylate in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lenvatinib Mesylate in Ewing Sarcoma Drug Details: Lenvatinib mesylate (Lenvima / Kisplyx / Lenvixi) is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Trabectedin in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Trabectedin in Ewing Sarcoma Drug Details: Trabectedin (Yondelis) is an anti tumor agent of marine...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Elimusertib in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Elimusertib in Ewing Sarcoma Drug Details: Elimusertib (BAY-1895344) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Ewing Sarcoma Drug Details: Regorafenib (BAY 73-4506, Stivarga) is an anti-neoplastic agent. Regorafenib...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Elraglusib in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Elraglusib in Ewing Sarcoma Drug Details: 9-ING41 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Palbociclib in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Palbociclib in Ewing Sarcoma Drug Details: Palbociclib (Ibrance) is a pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Abemaciclib in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Abemaciclib in Ewing Sarcoma Drug Details: Abemaciclib (Verzenio / Verzenios / Yulareb) is a benzimidazole...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Venetoclax in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Venetoclax in Ewing Sarcoma Drug Details: Venetoclax (ABT-199, GDC-0199/RG7601, Venclexta, Venclyxto) acts as an antineoplastic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Surufatinib in Ewing Sarcoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Surufatinib in Ewing Sarcoma Drug Details: Surufatinib (Sulanda) is a potential antineoplastic and anti-angiogenic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Devimistat in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Devimistat in Ewing Sarcoma Drug Details: Devimistat (CPI-613) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cabometyx in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cabometyx in Ewing Sarcoma Drug Details: Cabozantinib s-malate (Cabometyx, Aptimetyx) is a s-malate salt form...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – KB-0742 in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KB-0742 in Ewing Sarcoma Drug Details: KB-0742 is under development for the treatment of castration...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ESP-01 in Ewing Sarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ESP-01 in Ewing SarcomaDrug Details:ESP-01 is under development for the treatment of solid tumours including metastatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TP-1287 in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TP-1287 in Ewing Sarcoma Drug Details: TP-1287 is under development for the treatment of ewing...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.